Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hudson Resources Inc. stock logo
HUD
Hudson Resources
C$0.03
+20.0%		C$0.03
C$0.02
▼
C$0.08
C$5.45M2.0896,769 shs338,000 shs
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
$0.78
-1.6%		$0.86
$0.60
▼
$2.45
$32.58M1.54128,105 shs34,684 shs
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hudson Resources Inc. stock logo
HUD
Hudson Resources
0.00%0.00%0.00%0.00%0.00%
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
+3.21%-0.24%-10.63%-19.09%-44.89%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hudson Resources Inc. stock logo
HUD
Hudson Resources
C$0.03
+20.0%		C$0.03
C$0.02
▼
C$0.08
C$5.45M2.0896,769 shs338,000 shs
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
$0.78
-1.6%		$0.86
$0.60
▼
$2.45
$32.58M1.54128,105 shs34,684 shs
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hudson Resources Inc. stock logo
HUD
Hudson Resources
0.00%0.00%0.00%0.00%0.00%
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
+3.21%-0.24%-10.63%-19.09%-44.89%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Hudson Resources Inc. stock logo
HUD
Hudson Resources
0.00
N/AN/AN/A
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest BONH, HUD, LVCG, and MIRA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/20/2026
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/6/2026
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/24/2026
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 8/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Hudson Resources Inc. stock logo
HUD
Hudson Resources
N/AN/AC$0.00 per share30.00C$0.02 per shareN/A
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/AN/AN/AN/A$0.25 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Hudson Resources Inc. stock logo
HUD
Hudson Resources
C$4.34MC$0.021.26N/AN/AN/A384.69%-19.85%N/A
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-$10.44M-$1.24N/AN/AN/AN/A-106.95%-104.18%9/2/2026 (Estimated)

Latest BONH, HUD, LVCG, and MIRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/A-$0.03N/A-$0.03N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Hudson Resources Inc. stock logo
HUD
Hudson Resources
N/A2.94%N/AN/AN/A
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Hudson Resources Inc. stock logo
HUD
Hudson Resources
N/A
43.23
0.17
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/A
200.08
200.08

Institutional Ownership

CompanyInstitutional Ownership
Hudson Resources Inc. stock logo
HUD
Hudson Resources
N/A
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
35.16%

Insider Ownership

CompanyInsider Ownership
Hudson Resources Inc. stock logo
HUD
Hudson Resources
6.76%
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
19.89%
CompanyEmployeesShares OutstandingFree FloatOptionable
Hudson Resources Inc. stock logo
HUD
Hudson Resources
N/A181.64 millionN/ANot Optionable
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
242.02 million33.66 millionNot Optionable

Recent News About These Companies

MIRA Reports Positive Preclinical Results for Obesity Candidate SKNY-1
August 6, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/mira-reports-positive-preclinical-results-for-obesity-candidate-skny-1?utm_source=marketbeat.com&utm_medium=referral
MIRA Reports Positive 7-Day Dog Study Results for SKNY-1
August 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/mira-reports-positive-7-day-120000510.html
MIRA Pharmaceuticals Receives Nasdaq Minimum Bid Price Notice
July 31, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-receives-nasdaq-minimum-bid-price-notice?utm_source=marketbeat.com&utm_medium=referral
MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies
July 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/30/3335999/0/en/mira-pharmaceuticals-progresses-mira-55-and-skny-1-toward-ind-enabling-studies.html
MIRA Pharmaceuticals announces positive preclinical results for MIRA-55
July 10, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-announces-positive-preclinical-results-for-mira-55?utm_source=marketbeat.com&utm_medium=referral
MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain
July 10, 2026  |  accessnewswire.comA
MIRA Reports Positive Preclinical Data for SKNY-1 Program
July 6, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/mira-reports-positive-preclinical-data-for-skny-1-program?utm_source=marketbeat.com&utm_medium=referral
MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction
July 6, 2026  |  accessnewswire.comA
MIRA Unveils Differentiated Preclinical Data for Mira-55
June 25, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/mira-unveils-differentiated-preclinical-data-for-mira-55?utm_source=marketbeat.com&utm_medium=referral
MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC
June 25, 2026  |  accessnewswire.comA
MIRA Advances Ketamir-2 Into FDA-Accepted Phase 2a Trial
June 17, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/mira-advances-ketamir-2-into-fda-accepted-phase-2a-trial?utm_source=marketbeat.com&utm_medium=referral
MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy
June 17, 2026  |  accessnewswire.comA
MIRA Pharmaceuticals Appoints New Fractional Chief Financial Officer
June 8, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-appoints-new-fractional-chief-financial-officer?utm_source=marketbeat.com&utm_medium=referral
MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1
June 4, 2026  |  accessnewswire.comA
MIRA Expands Global Ketamir-2 License for Clinical Development
May 27, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/mira-expands-global-ketamir-2-license-for-clinical-development?utm_source=marketbeat.com&utm_medium=referral
MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN
May 27, 2026  |  accessnewswire.comA
Mira Pharmaceuticals stock gains on Phase 1 trial results
May 14, 2026  |  investing.comhttps://www.investing.com/news/stock-market-news/mira-pharmaceuticals-stock-gains-on-phase-1-trial-results-93CH-4688569
MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2
May 14, 2026  |  accessnewswire.comA
MIRA highlights SKNY-1 preclinical data in new publication
May 13, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/mira-highlights-skny-1-preclinical-data-in-new-publication?utm_source=marketbeat.com&utm_medium=referral
MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate
May 13, 2026  |  accessnewswire.comA

Media Sentiment Over Time

Hudson Resources stock logo

Hudson Resources CVE:HUD

C$0.03 +0.01 (+20.00%)
As of 03/19/2024

Hudson Resources Inc., a junior exploration company, engages in the mining, exploration, and development of mineral resources in Greenland. The company holds 100% interest in the Gronne Bjerg anorthosite project and a 31.1% interest in the White Mountain anorthosite mine. It also produces anorthosite mineral for various markets, such as e-glass fiberglass; white CO2 free cement; paints, coatings, and polymers; and alumina source. The company was formerly known as Tekwerks Solutions Inc. and changed its name to Hudson Resources Inc. in December 2002. Hudson Resources Inc. was incorporated in 2000 and is headquartered in Vancouver, Canada.

MIRA Pharmaceuticals stock logo

MIRA Pharmaceuticals NASDAQ:MIRA

$0.78 -0.01 (-1.62%)
Closing price 04:00 PM Eastern
Extended Trading
$0.78 +0.01 (+0.86%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas